These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 38009848)
1. Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region. Izumi T; Teramoto Y; Kamimura A; Doi R; Takai S; Mori T; Koizumi S; Kawahara Y; Aitake U; Lei X; Inomata N; Inafuku K; Nakamura Y J Dermatol; 2024 Feb; 51(2):271-279. PubMed ID: 38009848 [TBL] [Abstract][Full Text] [Related]
2. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients. Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098 [TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma. Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738 [TBL] [Abstract][Full Text] [Related]
4. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Ferrarotto R; Amit M; Nagarajan P; Rubin ML; Yuan Y; Bell D; El-Naggar AK; Johnson JM; Morrison WH; Rosenthal DI; Glisson BS; Johnson FM; Lu C; Mott FE; Esmaeli B; Diaz EM; Gidley PW; Goepfert RP; Lewis CM; Weber RS; Wargo JA; Basu S; Duan F; Yadav SS; Sharma P; Allison JP; Myers JN; Gross ND Clin Cancer Res; 2021 Aug; 27(16):4557-4565. PubMed ID: 34187851 [TBL] [Abstract][Full Text] [Related]
5. Management of locoregional recurrence in cutaneous squamous cell carcinoma of the head and neck. Strassen U; Hofauer B; Jacobi C; Knopf A Eur Arch Otorhinolaryngol; 2017 Jan; 274(1):501-506. PubMed ID: 27498202 [TBL] [Abstract][Full Text] [Related]
6. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970 [TBL] [Abstract][Full Text] [Related]
7. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457 [TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946 [TBL] [Abstract][Full Text] [Related]
9. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226 [TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. Zhang S; Chen J; Jiang H; Ma H; Yang B Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340 [TBL] [Abstract][Full Text] [Related]
12. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly. Haehl E; Rühle A; Klink R; Kalckreuth T; Sprave T; Gkika E; Zamboglou C; Meiß F; Grosu AL; Nicolay NH Radiat Oncol; 2021 Jun; 16(1):105. PubMed ID: 34118984 [TBL] [Abstract][Full Text] [Related]
13. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417 [TBL] [Abstract][Full Text] [Related]
14. Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study. Jiang J; Wu B; Sun Y; Xiang J; Shen C; He X; Ying H; Xia Z Cancer Immunol Immunother; 2024 Aug; 73(10):199. PubMed ID: 39105897 [TBL] [Abstract][Full Text] [Related]
15. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Okamoto I; Sato H; Tsukahara K Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271 [TBL] [Abstract][Full Text] [Related]
16. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051 [TBL] [Abstract][Full Text] [Related]
17. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study. Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M; PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck. Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096 [TBL] [Abstract][Full Text] [Related]
20. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]